In 1996, Jiří Žák, chairman & current CEO of FARMAK, took over the state-owned producer of vitamins FARMAKON where he previously worked for 30 years and turned it into a flourishing private company focused on the research, development, and production of active pharmaceutical ingredients (APIs), intermediates, and specialized chemicals. Žák shares the early success of FARMAK in the US and his internationalization strategy through its recent entry on the Brazilian and Japanese markets, as well as how the company has adapted to the evolution of the API industry and continued to remain sharp against fierce competition globally.
We are under pressure to develop new products to generate better income which means investing more in research
